203 related articles for article (PubMed ID: 11287641)
1. ANX7, a candidate tumor suppressor gene for prostate cancer.
Srivastava M; Bubendorf L; Srikantan V; Fossom L; Nolan L; Glasman M; Leighton X; Fehrle W; Pittaluga S; Raffeld M; Koivisto P; Willi N; Gasser TC; Kononen J; Sauter G; Kallioniemi OP; Srivastava S; Pollard HB
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4575-80. PubMed ID: 11287641
[TBL] [Abstract][Full Text] [Related]
2. Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7(+/-) mouse.
Srivastava M; Montagna C; Leighton X; Glasman M; Naga S; Eidelman O; Ried T; Pollard HB
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14287-92. PubMed ID: 14608035
[TBL] [Abstract][Full Text] [Related]
3. Significant allelic loss of ANX7region (10q21) in hormone receptor negative breast carcinomas.
Leighton X; Srikantan V; Pollard HB; Sukumar S; Srivastava M
Cancer Lett; 2004 Jul; 210(2):239-44. PubMed ID: 15183540
[TBL] [Abstract][Full Text] [Related]
4. ANX7 as a bio-marker in prostate and breast cancer progression.
Srivastava M; Bubendorf L; Nolan L; Glasman M; Leighton X; Miller G; Fehrle W; Raffeld M; Eidelman O; Kallioniemi OP; Srivastava S; Pollard HB
Dis Markers; 2001; 17(2):115-20. PubMed ID: 11673658
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients.
Srivastava M; Bubendorf L; Raffeld M; Bucher C; Torhorst J; Sauter G; Olsen C; Kallioniemi OP; Eidelman O; Pollard HB
Clin Cancer Res; 2004 Apr; 10(7):2344-50. PubMed ID: 15073110
[TBL] [Abstract][Full Text] [Related]
6. High frequency of deletion on chromosome 9p21 may harbor several tumor-suppressor genes in human prostate cancer.
Perinchery G; Bukurov N; Nakajima K; Chang J; Li LC; Dahiya R
Int J Cancer; 1999 Nov; 83(5):610-4. PubMed ID: 10521795
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of annexin VII expression in glioblastomas multiforme in humans.
Hung KS; Howng SL
J Neurosurg; 2003 Nov; 99(5):886-92. PubMed ID: 14609169
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X; Porter AT; Honn KV
Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.
Latini JM; Rieger-Christ KM; Wang DS; Silverman ML; Libertino JA; Summerhayes IC
J Urol; 2001 Nov; 166(5):1931-6. PubMed ID: 11586263
[TBL] [Abstract][Full Text] [Related]
10. Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q.
Yin Z; Babaian RJ; Troncoso P; Strom SS; Spitz MR; Caudell JJ; Stein JD; Kagan J
Oncogene; 2001 Apr; 20(18):2273-80. PubMed ID: 11402322
[TBL] [Abstract][Full Text] [Related]
11. Identification of a candidate tumor suppressor gene RHOBTB1 located at a novel allelic loss region 10q21 in head and neck cancer.
Beder LB; Gunduz M; Ouchida M; Gunduz E; Sakai A; Fukushima K; Nagatsuka H; Ito S; Honjo N; Nishizaki K; Shimizu K
J Cancer Res Clin Oncol; 2006 Jan; 132(1):19-27. PubMed ID: 16170569
[TBL] [Abstract][Full Text] [Related]
12. Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3.
Yin Z; Spitz MR; Babaian RJ; Strom SS; Troncoso P; Kagan J
Oncogene; 1999 Dec; 18(52):7576-83. PubMed ID: 10602517
[TBL] [Abstract][Full Text] [Related]
13. Loss of two new loci on chromosome 8 (8p23 and 8q12-13) in human prostate cancer.
Perinchery G; Bukurov N; Nakajima K; Chang J; Hooda M; Oh BR; Dahiya R
Int J Oncol; 1999 Mar; 14(3):495-500. PubMed ID: 10024682
[TBL] [Abstract][Full Text] [Related]
14. LAPSER1: a novel candidate tumor suppressor gene from 10q24.3.
Cabeza-Arvelaiz Y; Thompson TC; Sepulveda JL; Chinault AC
Oncogene; 2001 Oct; 20(46):6707-17. PubMed ID: 11709705
[TBL] [Abstract][Full Text] [Related]
15. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer.
Rubin MA; Gerstein A; Reid K; Bostwick DG; Cheng L; Parsons R; Papadopoulos N
Hum Pathol; 2000 Apr; 31(4):504-8. PubMed ID: 10821499
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity at chromosome arm 13q and RB1 status in human prostate cancer.
Latil A; Bièche I; Pesche S; Volant A; Valèri A; Fournier G; Cussenot O; Lidereau R
Hum Pathol; 1999 Jul; 30(7):809-15. PubMed ID: 10414500
[TBL] [Abstract][Full Text] [Related]
17. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes.
Kagan J; Stein J; Babaian RJ; Joe YS; Pisters LL; Glassman AB; von Eschenbach AC; Troncoso P
Oncogene; 1995 Nov; 11(10):2121-6. PubMed ID: 7478532
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma.
Ittmann MM
Prostate; 1996 May; 28(5):275-81. PubMed ID: 8610052
[TBL] [Abstract][Full Text] [Related]
19. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21.
Vocke CD; Pozzatti RO; Bostwick DG; Florence CD; Jennings SB; Strup SE; Duray PH; Liotta LA; Emmert-Buck MR; Linehan WM
Cancer Res; 1996 May; 56(10):2411-6. PubMed ID: 8625320
[TBL] [Abstract][Full Text] [Related]
20. Anx7 is required for nutritional control of gene expression in mouse pancreatic islets of Langerhans.
Srivastava M; Eidelman O; Leighton X; Glasman M; Goping G; Pollard HB
Mol Med; 2002 Dec; 8(12):781-97. PubMed ID: 12606813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
